Search
Search
About
Log in
Join
Experiences with
Enzalutamide
Posts
Communities
833 public posts
Filter results
A case to push for darolutamide.
The second-generation antiandrogen,
enzalutamide
, demonstrated full or partial activation of eight mutant variants, while the structurally distinct and most recently approved darolutamide demonstrated significant activation in only one mutant at concentrations up to 25 µM [21], which identifies a sequencing
The second-generation antiandrogen,
enzalutamide
, demonstrated full or partial activation of eight mutant variants, while the structurally distinct and most recently approved darolutamide demonstrated significant activation in only one mutant at concentrations up to 25 µM [21], which identifies a sequencing
KocoPr
in
Advanced Prostate Cancer
2 years ago
When to consider chemo?
He is planning to put me on
Enzalutamide
shortly and IMRT is a likely option further down the line when the ADT has shrunk the cancer. I am waiting for my appointment for a full body CT scan to see what the extent of the mets are.
He is planning to put me on
Enzalutamide
shortly and IMRT is a likely option further down the line when the ADT has shrunk the cancer. I am waiting for my appointment for a full body CT scan to see what the extent of the mets are.
Benkaymel
in
Fight Prostate Cancer
2 years ago
When to consider Chemo?
He is planning to put me on
Enzalutamide
shortly and IMRT is a likely option further down the line when the ADT has shrunk the cancer. I am waiting for my appointment for a full body CT scan to see what the extent of the mets are.
He is planning to put me on
Enzalutamide
shortly and IMRT is a likely option further down the line when the ADT has shrunk the cancer. I am waiting for my appointment for a full body CT scan to see what the extent of the mets are.
Benkaymel
in
Advanced Prostate Cancer
2 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Cellular and Genetic Clues that Drive BAT effectiveness
In TRANSFORMER it was shown that the presence of ARV-7 was a marker for worse outcomes with both BAT or with
enzalutamide
. 2) That BAT reduces the amount of AR in both cytoplasm and nucleus.
In TRANSFORMER it was shown that the presence of ARV-7 was a marker for worse outcomes with both BAT or with
enzalutamide
. 2) That BAT reduces the amount of AR in both cytoplasm and nucleus.
MateoBeach
in
Advanced Prostate Cancer
2 years ago
Now on ADT, what to add?
I have also been looking at adding either
Enzalutamide
(Xtandi), Darolutamide or even Apalutamide. Can anyone suggest what may be the best one to add to my current ADT that may improve life expectancy without too many additional side effects. Thank you in advance.
I have also been looking at adding either
Enzalutamide
(Xtandi), Darolutamide or even Apalutamide. Can anyone suggest what may be the best one to add to my current ADT that may improve life expectancy without too many additional side effects. Thank you in advance.
x-rays1
in
Advanced Prostate Cancer
2 years ago
A very cool link for all inhibitors that you can download
Enzalutamide
(MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells.
Enzalutamide
is shown to increase autophagy. Bicalutamide (ICI-176334) is an androgen receptor (AR) antagonist with IC50 of 0.16 μM in LNCaP/AR(cs)cell line. Bicalutamide promotes autophagy.
Enzalutamide
(MDV3100) is an androgen-receptor (AR) antagonist with IC50 of 36 nM in LNCaP cells.
Enzalutamide
is shown to increase autophagy. Bicalutamide (ICI-176334) is an androgen receptor (AR) antagonist with IC50 of 0.16 μM in LNCaP/AR(cs)cell line. Bicalutamide promotes autophagy.
KocoPr
in
Advanced Prostate Cancer
2 years ago
Benefit of "triplet therapy" confirmed with enzalutamide too
Enzalutamide
(Xtandi) joins abiraterone (Zytiga) and darolutamide (Nubeqa) in showing usefulness in triplet therapy added to docetaxel and ADT.
Enzalutamide
(Xtandi) joins abiraterone (Zytiga) and darolutamide (Nubeqa) in showing usefulness in triplet therapy added to docetaxel and ADT.
Tall_Allen
in
Advanced Prostate Cancer
2 years ago
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AF
Analyses of all three trials pooled and AFFIRM+PREVAIL pooled revealed that statin but not metformin use was significantly associated with a reduced risk of death in
enzalutamide
-treated patients.
Analyses of all three trials pooled and AFFIRM+PREVAIL pooled revealed that statin but not metformin use was significantly associated with a reduced risk of death in
enzalutamide
-treated patients.
cigafred
in
Advanced Prostate Cancer
2 years ago
Enzalutamide and Pluvicto
My question is: A) Should he start
enzalutamide
now or sometime before the scan to make sure his PSMA is fully expressed? B) Should he start taking
enzalutamide
after the scan but before treatment begins? Or, C)
Enzalutamide
doesn’t really add that much benefit.
My question is: A) Should he start
enzalutamide
now or sometime before the scan to make sure his PSMA is fully expressed? B) Should he start taking
enzalutamide
after the scan but before treatment begins? Or, C)
Enzalutamide
doesn’t really add that much benefit.
leebeth
in
Advanced Prostate Cancer
2 years ago
'Substandard' Control Arms in Clinical Trials– Practice found common in prostate cancer studies
The trial included patients with metastatic castration-resistant prostate cancer (mCRPC) with a mutation of a predefined set in a DNA repair gene that had progressed on at least one androgen receptor targeting agent (ARTA),
enzalutamide
or abiraterone.
The trial included patients with metastatic castration-resistant prostate cancer (mCRPC) with a mutation of a predefined set in a DNA repair gene that had progressed on at least one androgen receptor targeting agent (ARTA),
enzalutamide
or abiraterone.
GeorgeGlass
in
Advanced Prostate Cancer
2 years ago
PSA rise
My dad is on
enzalutamide
but his PSA has been bouncing around the past 7/8 months from 7-12.5 (sometimes up and then down). His doctors don’t seem to be phased by this, I don’t know whether the approach is different here in the UK but I don’t know why they aren’t reacting.
My dad is on
enzalutamide
but his PSA has been bouncing around the past 7/8 months from 7-12.5 (sometimes up and then down). His doctors don’t seem to be phased by this, I don’t know whether the approach is different here in the UK but I don’t know why they aren’t reacting.
SC19
in
Advanced Prostate Cancer
2 years ago
Sacral mass
I have something called a sacral mass on my sacrum with lesions in S1 & S2 as my metastatic site I’m on
Enzalutamide
and Zoladex which has kept everything at bay for the last 6 months since diagnosis My concerns are that being where it is it likely to leave me wheelchair bound I can’t get any real answers
I have something called a sacral mass on my sacrum with lesions in S1 & S2 as my metastatic site I’m on
Enzalutamide
and Zoladex which has kept everything at bay for the last 6 months since diagnosis My concerns are that being where it is it likely to leave me wheelchair bound I can’t get any real answers
Farn
in
Advanced Prostate Cancer
2 years ago
Re: Safety of Zytiga & Xtandi
"Compared with men not receiving
enzalutamide
, men receiving
enzalutamide
were at an increased risk of a major composite adverse event (HR = 1.22 ///) but not a minor composite adverse event (HR = 1.04 ...)" This is in addition to any risk posed by classic ADT.
"Compared with men not receiving
enzalutamide
, men receiving
enzalutamide
were at an increased risk of a major composite adverse event (HR = 1.22 ///) but not a minor composite adverse event (HR = 1.04 ...)" This is in addition to any risk posed by classic ADT.
pjoshea13
in
Advanced Prostate Cancer
2 years ago
Estradiol Clinical Trial in UK?
Since my diagnosis of hormone-resistant and metastatic, I've been researching my options, beyond SOC (my onco wants me to start
enzalutamide
+ Leuprorolin immediately) .
Since my diagnosis of hormone-resistant and metastatic, I've been researching my options, beyond SOC (my onco wants me to start
enzalutamide
+ Leuprorolin immediately) .
CrocodileShoes
in
Advanced Prostate Cancer
2 years ago
Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016
This post is prompted by Scout4answers': "
Abiraterone and
Raise Metabolic, Cardiovascular Adverse Event Risks" [2] I think an August 5, 2021 JAMA paper will give some perspective of historic alternative causes of death: "
Causes of Death Among Patients With Metastatic Prostate
This post is prompted by Scout4answers': "
Abiraterone and
Raise Metabolic, Cardiovascular Adverse Event Risks" [2] I think an August 5, 2021 JAMA paper will give some perspective of historic alternative causes of death: "
Causes of Death Among Patients With Metastatic Prostate
pjoshea13
in
Advanced Prostate Cancer
2 years ago
Bye bye, Bical, what's next?
It appears though both
enzalutamide
and apalutamide are approve in the UK. Some a couple of questions to you all: 1. Is any singificant difference between the two? 2. Does BAT favour a particular 'amide', or will any of that class work? Will let you know his recommendations
It appears though both
enzalutamide
and apalutamide are approve in the UK. Some a couple of questions to you all: 1. Is any singificant difference between the two? 2. Does BAT favour a particular 'amide', or will any of that class work? Will let you know his recommendations
CrocodileShoes
in
Advanced Prostate Cancer
2 years ago
GA 68 PSMA PET SCAN RESULTS
Tall Allen, I read the SPPORT Trial you sent me and if I understand correctly it looks like the next line of treatment should be RT to the pelvic bed and the lymph nodes, possibly administering Apalutamide vs. abiraterone or
enzalutamide
.
Tall Allen, I read the SPPORT Trial you sent me and if I understand correctly it looks like the next line of treatment should be RT to the pelvic bed and the lymph nodes, possibly administering Apalutamide vs. abiraterone or
enzalutamide
.
GMan-62
in
Advanced Prostate Cancer
2 years ago
Enough is Enough - Alicia Morgans, MD, MPH,
Subsequent data from ARCHES and ENZAMET demonstrated improved survival with treatment intensification with ADT and
enzalutamide
, and TITAN demonstrated that ADT plus apalutamide also prolongs survival versus ADT.
Subsequent data from ARCHES and ENZAMET demonstrated improved survival with treatment intensification with ADT and
enzalutamide
, and TITAN demonstrated that ADT plus apalutamide also prolongs survival versus ADT.
Hawk56
in
Advanced Prostate Cancer
2 years ago
Rezvilutamide: new anti-androgen is better than Casodex added to ADT for newly diagnosed high-met HSPC. But is field too crowded?
With Zytiga (abiraterone), Xtandi (
enzalutamide
), and Erleada (apalutamide) and docetaxel already approved for this purpose, I don't know whether Jiangsu Hengrui will be able to make significant inroads into the market, unless they are able to compete on price.
With Zytiga (abiraterone), Xtandi (
enzalutamide
), and Erleada (apalutamide) and docetaxel already approved for this purpose, I don't know whether Jiangsu Hengrui will be able to make significant inroads into the market, unless they are able to compete on price.
Tall_Allen
in
Advanced Prostate Cancer
2 years ago
My Turn to Ask a Question
After nine years and four months on Zoladex (goserelin) and the last five years on Xtandi (
enzalutamide
) plus Zoladex my PSA has started to slowly climb. It is still very low (2.6) but my oncologist wants to move to the next stage before my PSA gets much higher.
After nine years and four months on Zoladex (goserelin) and the last five years on Xtandi (
enzalutamide
) plus Zoladex my PSA has started to slowly climb. It is still very low (2.6) but my oncologist wants to move to the next stage before my PSA gets much higher.
RyderLake2
in
Advanced Prostate Cancer
2 years ago
1
...
14
15
16
...
42
Next page
10
20
30
40
Filter results
Clear filters
Posted in
All communities
Advanced Prostate Cancer
760 results
Fight Prostate Cancer
56 results
Prostate Cancer Network
7 results
View top 10 communities
Sort by
Most Relevant
Newest